FDA’s Overcaution Carries Deadly Consequences

December 10, 2018

When the FDA sets out to evaluate a potential new drug, the agency’s overcaution makes the exercise more expensive and potentially deadly from patients who might benefit. Mark Flatten of the Goldwater Institute comments.

Download:mp3


Subscribe to Cato Daily Podcast:

Subscribe on iTunes Get it on Google Play Subscribe via RSS

Recent Cato Daily Podcast